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Fig. 1. Confocal microscopy of ANCA binding to neutrophils (A, anti-PR3 positive; B, anti-PR3 negative). Neutrophils were purified from healthy
volunteers by density centrifugation and residual erythrocytes were removed by hypotonic lysis. Cells were primed with 10 ng/mL TNFa for
15 minutes at 37
◦
C and washed twice. They were then incubated sequentially for 30 minutes each with serum (1:10) from patients with anti-PR3
antibody positive vasculitis (A1 and 2; N = 2) or anti-PR3 antibody negative crescentic nephritis (B1 and 2; N = 2), alexafluor-568 conjugated
antihuman IgG (1:50; Molecular Probes, OR, USA) and FITC-conjugated anti-CD16 (1:100; Caltag, CA, USA). After washing 3 times in PBS,
cells were fixed in cold 1% paraformaldehyde and images were captured using laser scanning confocal microscopy using the same settings for each
condition (LSM Pascal, Zeiss, Germany). Images are representative of 3 separate experiments.
LYN R. AMBROSE, MARK A. LITTLE, SUSSAN NOURSHARGH,
and CHARLES D. PUSEY
London, United Kingdom
Correspondence to Prof. Charles Pusey, Renal Section, Division of
Medicine, Imperial College London, Hammersmith Campus, London
W12 0NN, UK.
E-mail: c.pusey@imperial.ac.uk
REFERENCES
1. VAN ROSSUM AP, VAN DER GELD YM, LIMBURG PC, et al: Human anti-
neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA)
bind to neutrophils. Kidney Int 68:537–541, 2005
2. ABDEL-SALAM B, IKING-KONERT C, SCHNEIDER M, et al: Autoanti-
bodies to neutrophil cytoplasmic antigens (ANCA) do not bind to
polymorphonuclear neutrophils in blood. Kidney Int 66:1009–1017,
2004
3. FALK RJ, TERRELL RS, CHARLES LA, et al: Anti-neutrophil cytoplas-
mic autoantibodies induce neutrophils to degranulate and produce
oxygen radicals in vitro. Proc Natl Acad Sci U S A 87:4115–4119,
1990
Daily dialysis, nocturnal
dialysis, and randomized
controlled trials: Are we
asking the right questions?
To the Editor: The systematic review by Walsh et al
[1] raises an important point in new dialysis schedules,
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particularly in cases such as daily dialysis, for which
there is a very appealing physiologic-philosophical back-
ground, but comparatively little “primary” evidence [2].
In such a context, it is customary to highlight the need for
randomized controlled trials (RCTs); however, we would
like to discuss not only on the ethical aspects of random-
ization of “intrusive” treatments, but also on the technical
feasibility. In fact, the “ideal” RCT should be blinded, ap-
plied to the overall population, have a low attrition bias,
be performed long enough to allow the evaluation of hard
outcomes. None of these assumptions are fully applicable
to this case. Blinding is not possible; the subset of patients
agreeing to be randomized is probably as low as 50% [3,
4]. A strong attrition bias is expected, with shift towards
the modality most fit to patients’ preferences.
These problems, already faced in the case of peri-
toneal dialysis versus hemodialysis (intrusiveness), or in
the Modification of Diet in Renal Disease (MDRD) study
(attrition bias), in turn raise questions on the goals of such
a study. In fact, do we really want a “one size fits all” dialy-
sis schedule, or are we trying to give each patient a further
possibility to improve the quality and (possibly) the quan-
tity of life? In the latter case, we probably do not need
an RCT, but well-designed observational studies that may
give a measure of the advantages in patients who, for per-
sonal, organizational, or clinical reasons are willing to try
these demanding, albeit promising schedules.
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Reply from the Authors
Piccoli et al detail many potential barriers to the com-
pletion of the “ideal” randomized controlled trial (RCT)
in sustained hemodialysis (HD) (short daily and noctur-
nal HD). In response to these obstacles, they argue that
information (quality and quantity of life) needed to tai-
lor dialysis to the individual patient can be obtained from
observational studies.
Admittedly, several barriers will prevent an ‘ideal’
RCT in sustained HD (or an ‘ideal’ RCT in any other
area of medicine). It would appear to us that the ethics of
randomizing patients (with informed consent) to an intru-
sive intervention is more satisfactory than recommend-
ing patients perform an unproven intrusive intervention.
Bias in the assessment of study outcomes could feasibly
be reduced by blinding the outcome assessors as well as
the data analysts [1]. The mere fact that patients con-
sent to an RCT limits the generalizability of the results.
However, clinicians must deal with this issue in the inter-
pretation and application of any RCT. Attrition bias can
be reduced by an appropriate sample size calculation and
statistical techniques, including intention-to-treat analy-
ses. Finally, although all areas of medicine should strive
for evidence supported by hard end point trials, impor-
tant health outcomes, such as regression of left ventricular
mass and health-related quality of life, may be adequately
addressed in short-term studies.
The number of RCTs published in nephrology is
less than all other internal medicine specialties [2].
Relying on data from observational studies, as sug-
gested by Piccoli et al, has led to wasted time and re-
sources, as exemplified by enthusiasm for normalization
of hemoglobin and higher small solute clearances. In-
stead of defining obstacles for the inception and com-
pletion of RCTs, the nephrology community should be
greeting RCTs with enthusiasm. Given that there is sig-
nificant uncertainty around the costs, safety, and effec-
tiveness of sustained HD [3], performance of an RCT
comparing sustained HD and conventional HD should be
seen as a necessity to improve tailored dialysis decision
making.
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